Abstract
Nodular sclerosis is the most commonly recognized histopathologic subtype of Hodgkin’s disease in many studies [1–5]. In the clinical trials of the British National Lymphoma Investigation (BNLI) [6], 75% of the cases have been classified as nodular sclerosis. Cellular nodules may have a wide variety of histologic appearances which may range from a predominance of lymphocytes to lymphocyte depletion with numerous Hodgkin’s cells [7]. A clear need has emerged for further histopathologic subdivision within this group in order to provide additional prognostic information. Several reports on this theme have been published, but the numbers of cases examined in these studies have been rather small [8–13]. In two previous publications we described the prognostic significance of a cytologic subdivision of nodular sclerosing Hodgkin’s disease in a group of laparotomized or Stage IV patients [14] and in a group of patients who had not undergone staging laparotomy [15]. We now present the combined results of our histologic analysis of 1156 cases of nodular sclerosing Hodgkin’s disease included in which are patients from the previous two studies. The prognostic significance of this cytologic subdivision is discussed and the relationship to anatomic stage is reviewed.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Kadin ME, Glatstein E and Dorfman RF (1971). Clinical-pathologic studies of 117 untreated patients subjected to laparotomy for the staging of Hodgkin’s disease. Cancer 27: 1277–1294.
Chelloul N, Burke J, Motteram R et al. (1972). HL-A antigens and Hodgkin’s disease. Report on the histological analysis. In: Histocompatibility Testing. Copenhagen: Munkgaard.
Kirschener RH, Abt AB, O’Connell MJ et al. (1974). Vascular invasion and hematogenous dissemination of Hodgkin’s disease. Cancer 34: 1159–1162.
Kaplan HS (1980). Hodgkin’s Disease. 2nd ed. Cambridge. Mass.: Harvard University Press.
Bergsagel DE, Alison RE, Beon HA et al. (1982). Results of treating Hodgkin’s disease without a policy of staging laparotomy. Cancer Treat Rep 66: 717–731.
Jelliffe AM and Vaughan Hudson G (1981). The evolution of the British National Lymphoma Investigation. Clin Radiol 32: 483–490.
Noiman RS (1978). Current problems in the histopathological diagnosis and classification of Hodgkin’s disease. Path Ann 13: 289–328.
Cross RM (1968). A clinicopathologic study of nodular sclerosing Hodgkin’s disease. J Clin Path 21: 303–331.
Keller AR, Kaplan HS, Lukes RJ and Rappaport H (1968). Correlation of histopathology with other prognostic indicators in Hodgkin’s disease. Cancer 22: 437–499.
Patchevsky AS, Brodovsky H, Southard M et al. (1973). Hodgkin’s disease. A clinical and pathological study of 235 cases. Cancer 32: 150–161.
Cionini L, Argonini L, Biti GP and Bondi R (1978). Prognostic significance of histologic subdivision of Hodgkin’s disease nodular sclerosis. Acta Radiologica (Oncology) 17: 6573.
Carbone A (1979). Histologic subclassification of nodular sclerosis Hodgkin’s disease. Tumori 65: 743–751.
Mann RB, Jaffee ES and Berard CW (1979). Malignant lymphomas, a conceptual understanding of morphologic diversity. Amer J Path 94: 103–192.
Bennett MH, Tu A and Vaughan Hudson B (1981). Analysis of grade 1 Hodgkin’s disease. Clin Radiol 32: 491–498.
Bennett MH, MacLennan KA, Easterling MJ et al. (1983). The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin’s disease: An analysis of 271 non-laparotomised cases. Clin Radiol 34: 497–501.
Lukes RJ and Butler JJ (1966). The pathology and nomenclature of Hodgkin’s disease. Cancer Res 26: 1063–1081.
Lukes RJ (1971). Criteria for involvement of lymph node, bone marrow, spleen and liver in Hodgkin’s disease. Cancer Res 31: 1755–1767.
Peto R, Pike MC, Armitage P et al. (1977). Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1–39.
MacLennan KA, Vaughan Hudson B, Easterling MJ et al. (1983). The presentation haemoglobin level in 1103 patients with Hodgkin’s disease. Clin Radiol 34: 491–495.
MacLennan KA, Vaughan Hudson B, Jelliffe AM et al. (1981). The pretreatment peripheral blood lymphocyte count in 1100 patient with Hodgkin’s disease: The prognostic significance and the relationship to the presence of systemic symptoms. Clin Oncol 7: 333–339.
Jackson H Jr and Parker F Jr (1947). Hodgkin’s Disease and Allied Disorders. New York: Oxford University Press.
Jelliffe AM and Thompson AD (1955). The prognosis in Hodgkin’s disease. Brit J Cancer 9: 21–36.
Smetana HF and Cohen BM (1956). Mortality in relation to histologic type in Hodgkin’s disease. Blood 11: 211–224.
Lukes RJ (1963). Relationship of histologic features to clinical stage in Hodgkin’s disease. Amer J Roentgenol 90: 944–955.
Lukes RJ, Butler JJ and Hickes EB (1966). Natural history of Hodgkin’s disease as related to its pathologic picture. Cancer 19: 317–344.
Strum SB and Rappaport H (1971). Interrelations of the histologic types of Hodgkin’s disease. Arch Path 91: 127–134.
Tubiana M, Attie E, Flamant R et al. (1971). Prognostic factors in 454 cases of Hodgkin’s disease. Cancer Res 31: 1801–1810.
Hoppe RT, Cox RS, Rosenberg SA and Kaplan HS (1982). Prognostic factors in pathologic Stage III Hodgkin’s disease. Cancer Treat Rep 66: 743–749.
Colby TV, Hoppe RT and Warnke RA (1982). Hodgkin’s disease: A clinicopathologic study of 659 cases. Cancer 49: 1848–1858.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Martinus Nijhoff Publishers, Boston
About this chapter
Cite this chapter
MacLennan, K.A. et al. (1985). Prognostic significance of cytologic subdivision in nodular sclerosing Hodgkin’s disease: An analysis of 1156 patients. In: Cavalli, F., Bonadonna, G., Rozencweig, M. (eds) Malignant Lymphomas and Hodgkin’s Disease: Experimental and Therapeutic Advances. Developments in Oncology, vol 32. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2607-6_20
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2607-6_20
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9632-4
Online ISBN: 978-1-4613-2607-6
eBook Packages: Springer Book Archive